caa a22 4500 47707264X CHVBK 20180405111430.0 cr unu---uuuuu 170330e19961001xx s 000 0 eng 10.1007/BF00823593 doi (NATIONALLICENCE)springer-10.1007/BF00823593 Intravenous propafenone: Efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation—A single-blind placebo-controlled study [Elektronische Daten] [Francesco Bellandi, roberto Dabizzi, Fabrizio Cantini, Massimo Di Natale, Laura Niccoli] Summary: The effectiveness of intravenous propafenone for conversion to sinus rhythm (SR) of paroxysmal atrial fibrillation (AF), lasting less than 7 days, was evaluated with a single-blind, randomized, placebo-controlled study, given the possible spontaneous conversion of this arrhythmia. Group 1 (98 patients) received intravenous propafenone (2 mg/kg iv over 10 minutes followed by 0.007 mg/kg/min); and group 2 (84 patients) received intravenous placebo (0.9% saline solution). The infusion was continued until restoration of SR but no longer than 24 hours. Eight-nine patients (90.8%) received propafenone and 27 patients (32%) receiving placebo were converted to SR (p<0.005). The mean conversion time was 2.46±2.59 hours in group 1 and 17.15±5.78 hours in group 2 (p<0.005). In patients treated with propafenone, conversion of SR mostly occurred in the first 4 hours (86.5%), considered to be the optimal infusion time in our experience. In both groups, the left atrial size was significantly larger in nonconverted than in converted patients. Similarly, the duration of the arrhythmia was significantly longer in nonconverted patients. In nonconverted patients, the mean ventricular rate decreased from 143±beats/min to 101±18 beats/min after propafenone and from 135±19 beats/min to 199 ±16 beats/min after placebo (group 1 vs. group 2: p<0.005). Two episodes of sinus standstill (3.4 and 3.8, seconds, respectively) occurred at SR restoration obtained with propafenone. Intravenous propafenone is an effective, safe, and usually rapid drug for AF treatment. Moreover, it produces a real and significant reduction in the mean ventricular rate in nonconverted patients. Kluwer Academic Publishers, 1996 atrial fibrillation nationallicence antiarrhythmic agents nationallicence propafenone nationallicence Bellandi Francesco Second Divisione di Medicina, Ospedale Misericordia e Dolce, Prato, Italy aut Dabizzi roberto Clinica Medica I°, University of Florence, Italy aut Cantini Fabrizio Second Divisione di Medicina, Ospedale Misericordia e Dolce, Prato, Italy aut Di Natale Massimo First Divisione di Medicina, Ospedale Misericordia e Dolce, Prato, Italy aut Niccoli Laura aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/2(1996-10-01), 153-157 0920-3206 10:2<153 1996 10 10557 https://doi.org/10.1007/BF00823593 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00823593 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bellandi Francesco Second Divisione di Medicina, Ospedale Misericordia e Dolce, Prato, Italy aut NATIONALLICENCE 700 1- Dabizzi roberto Clinica Medica I°, University of Florence, Italy aut NATIONALLICENCE 700 1- Cantini Fabrizio Second Divisione di Medicina, Ospedale Misericordia e Dolce, Prato, Italy aut NATIONALLICENCE 700 1- Di Natale Massimo First Divisione di Medicina, Ospedale Misericordia e Dolce, Prato, Italy aut NATIONALLICENCE 700 1- Niccoli Laura aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/2(1996-10-01), 153-157 0920-3206 10:2<153 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer